Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies
| Autor: | Dario Zava, Gianni Allais, Deborha Pezzola, Stefano Omboni, Vincenzo Tullo, Chiara Benedetto, Gennaro Bussone |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Migraine Disorders
Population Almotriptan Carbazoles Clinical Neurology Zolmitriptan Triptans Dermatology Contraceptives Oral Hormonal Premenstrual Syndrome Double-Blind Method Medicine Humans Multicenter Studies as Topic education Oxazolidinones Randomized Controlled Trials as Topic education.field_of_study Oral-contraceptive induced menstrual migraine Cross-Over Studies Estrogen withdrawal business.industry Rizatriptan General Medicine Triazoles medicine.disease Crossover study Tryptamines Menstruation Serotonin Receptor Agonists Psychiatry and Mental health Migraine Symposium - the Important Thing Is Not to Stop Questioning Anesthesia Female Neurology (clinical) business Frovatriptan medicine.drug |
| Zdroj: | Neurological Sciences |
| ISSN: | 1590-1874 |
| DOI: | 10.1007/s10072-013-1393-x |
| Popis: | Oral contraceptive-induced menstrual migraine (OCMM) is a particularly severe form of migraine triggered by the cyclic hormone withdrawal. To review the efficacy of frovatriptan vs. other triptans, in the acute treatment of OCMM through a pooled analysis of three individual randomized Italian studies. With or without aura migraineurs were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). All studies had a multicenter, randomized, double-blind, crossover design. After treating 1–3 episodes of migraine in 3 months with the first treatment, patients switched to the other treatment for the next 3 months. In this analysis, the subset of 35 of the 280 women of the intention-to-treat population taking combined oral contraceptives and experiencing a migraine attack during the withdrawal phase, were analyzed. The proportion of pain free and pain relief at 2 h were 25 and 51 % with frovatriptan and 28 and 48 % with comparators (p = NS). At 24 h, 71 and 83 % of frovatriptan-treated patients and 60 and 76 % of comparator-treated patients were pain free (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|